Cargando…

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data

Background: Improve the treatment quality might affect patients’ efficacy and survival. Methods: Five hundred thirty multiple myeloma patients treated in four hematological centers in China from February 2006 to August 2018 were enrolled. General characteristics, treatment regimens and cycles, effic...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Jingsong, He, Donghua, Han, Xiaoyan, Zheng, Gaofeng, Wei, Guoqing, Zhao, Yi, Yang, Yang, Wu, Wenjun, Fu, Jiaping, Shou, Lihong, Kong, Hongwei, Huang, He, Cai, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759685/ https://www.ncbi.nlm.nih.gov/pubmed/33362538 http://dx.doi.org/10.3389/fphar.2020.561601

Ejemplares similares

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients
por: Zheng, Gaofeng, et al.
Publicado: (2022)

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China
por: Chen, Qingxiao, et al.
Publicado: (2022)

High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
por: Yang, Li, et al.
Publicado: (2018)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients
por: Yue, Xiaoyan, et al.
Publicado: (2022)

Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
por: Yao, Rongxin, et al.
Publicado: (2019)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen
por: Kim, Su-In, et al.
Publicado: (2022)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients
por: Zhou, Qiaolin, et al.
Publicado: (2022)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis
por: Xie, Chunhong, et al.
Publicado: (2022)

Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
por: Mersin, Sinan, et al.
Publicado: (2021)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
por: Liu, Xiao, et al.
Publicado: (2022)

Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
por: Xu, Peipei, et al.
Publicado: (2019)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study
por: Chen, Runzhe, et al.
Publicado: (2017)

Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety
por: Zhai, Yujia, et al.
Publicado: (2021)

Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods
por: Zhang, Hong-Mei, et al.
Publicado: (2019)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis
por: Sun, Chun-yan, et al.
Publicado: (2017)

Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
por: Ashrafi, Farzaneh, et al.
Publicado: (2020)

Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
por: Narsipur, Nihal, et al.
Publicado: (2021)

Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma
por: Han, Xiaoyan, et al.
Publicado: (2017)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
por: Wei, GuoQing, et al.
Publicado: (2017)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma
por: Hu, Min, et al.
Publicado: (2023)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
por: Tibullo, Daniele, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
por: Cao, Yaohua, et al.
Publicado: (2021)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t8m8rod7ir4p44d59ed1cbeqed